This month, the Journal of the Generics and Biosimilars Initiative (GaBI Journal) published a whitepaper entitled “US biosimilars marketplace on pace with Europe”. The article is co-authored by ASBM’s Executive Director Michael Reilly and its Chair, Madelaine Feldman, MD, FACR.
The paper explores in detail the considerable successes of the U.S. biosimilar pathway in its first 10 years, including the approval of 28 biosimilars and launch of 18 of these in just over five years’ time. In addition, the paper examines how competition between multiple biosimilars are increasingly leading to lower prices and greater biosimilar market share. From the paper:
In the US, biosimilars have gained significant share in the majority of therapeutic areas in which they have been introduced, ranging on average from 20% to 25% within the first year of launch, with some projected to reach greater than 50% within the first 2 years. As expected, first-to-market biosimilars tend to capture a greater portion of the segment compared to later entrants. Filgrastim biosimilars have been on the market the longest at 5 years and have achieved a 72% share, while bevacizumab and trastuzumab biosimilars have approximately 40% share. Rituximab and infliximab have had the most limited adoption, with approximately 20% market share.
The paper will also be published in Issue 4 of its 2020 print edition.
Read the article now at Gabi’s website here.